Denali Therapeutics Inc.

Last updated September 27, 2026
Favorite this organization

Organization details

Legal name
Denali Therapeutics Inc.
Ownership
Public
Status
Active
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
South SAN Francisco
Headquarters state / province
California
Headquarters country
United States
Fiscal year end
December
Ticker symbol
DNLI
Primary stock exchange
Nasdaq

Identifiers

SEC CIK
0001714899
EIN
46-3872213

Board of directors

Follow this board

Chief executives

Ryan J. Watts · President and CEO
Dates unknown

Director election results

Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

13 of this board's directors also sit on 33 other boards.

Network of Denali Therapeutics Inc.'s board connections ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals... BeOne Medicines Ltd. BeOne Medicines Ltd. Bicycle Therapeutics plc Bicycle Therapeutics p... DBV Technologies S.A. DBV Technologies S.A. Immunocore Holdings plc Immunocore Holdings pl... Incyte Corp. Incyte Corp. Kiniksa Pharmaceuticals International plc Kiniksa Pharmaceutical... Kodiak Sciences Inc Kodiak Sciences Inc Kymera Therapeutics Inc. Kymera Therapeutics In... Madrigal Pharmaceuticals Inc. Madrigal Pharmaceutica... Neurogene Inc. Neurogene Inc. Prelude Therapeutics Incorporated Prelude Therapeutics I... Regeneron Pharmaceuticals Inc. Regeneron Pharmaceutic... Replimune Group Inc. Replimune Group Inc. TScan Therapeutics Inc. TScan Therapeutics Inc... vTv Therapeutics Inc. vTv Therapeutics Inc. David P. Schenkein David P. Schenkein Felix Baker Felix Baker Julian Baker Julian Baker Marc Tessier-Lavigne Marc Tessier-Lavigne Denali Therapeutics Inc.
Shared director Other board Same sector +17 more in the list below

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$0
0 purchases by 0 insiders
Sold, last 12 months
$1,300,167
7 sales by 4 insiders
Date Insider Transaction Shares Price Value
Sep 4, 2026 Chin Peter Scott Officer (Chief Medical Officer) Open-market sale −1,654 $22.29 $36,868
Sep 2, 2026 Nancy Thornberry Director Open-market sale −10,824 $22.85 $247,328
Sep 2, 2026 Nancy Thornberry Director Open-market sale −615 $23.74 $14,600
Sep 1, 2026 Schuth Alexander O. Officer (COFO and Secretary) Open-market sale −2,768 $23.44 $64,882
Aug 12, 2026 Ryan J. Watts Director, Officer (President and CEO) Gift −32,220 — —
Aug 11, 2026 Schuth Alexander O. Officer (COFO and Secretary) Open-market sale −2,857 $25.07 $71,625
Jun 3, 2026 Jay T. Flatley Director Grant or award +6,408 — —
Jun 3, 2026 Peter S. Klein Director Grant or award +6,408 — —
Jun 3, 2026 Steve E. Krognes Director Grant or award +6,408 — —
Jun 3, 2026 David P. Schenkein Director Grant or award +6,408 — —
Jun 3, 2026 Nancy Thornberry Director Grant or award +6,408 — —
Jun 3, 2026 Hauwermeiren Timothy Van Director Grant or award +6,408 — —
Jun 3, 2026 Jennifer E. Cook Director Grant or award +6,408 — —
Jun 3, 2026 Baker Brothers Life Sciences LP Director Grant or award +6,408 — —
Jun 3, 2026 Baker Brothers Life Sciences LP Director Grant or award +6,408 — —

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.